Citations

Clear

1011 citation(s) found for "Barry, WT".

The reservoir-wave approach to characterize pulmonary vascular-right ventricular interactions in humans
Andersen, Mads J. , Burrowes, Lindsay M. , Bouwmeester, J. Christopher , Belenkie, Israel, Borlaug, Barry A. , Tyberg, John V. , Ghimire, Anukul , Grant, Andrew D. , Fine, Nowell Mark , Borlaug, Barry A , Andersen, Mads Jønsson

Mayo Clinic

Journal of Applied Physiology | October 20, 2016 | Volume: 121 | Issue: 6 | Pages: 1348-1353

10.1152/japplphysiol.00697.2016 | PMID 27765845 Get It

Using the reservoir-wave approach (RWA) we previously characterized pulmonary vasculature mechanics in a normal canine model. We found reflected backward-traveling waves that decrease pressure and increase flow in the proximal pulmonary artery (PA). These waves decrease right ventricular (RV) afterload and facilitate RV ejection. With pathological alterations to the pulmonary vasculature, these waves may change and impact RV performance. Our objective in this study was to characterize PA wave reflection and the alterations in RV performance in cardiac patients, using the RWA. PA pressure, Doppler-flow velocity, and pulmonary arterial wedge pressure were measured in 11 patients with exertional dyspnea. The RWA was employed to analyze PA pressure and flow; wave intensity analysis characterized PA waves. Wave-related pressure was partitioned into two components: pressures due to forward-traveling and to backward-traveling waves. RV performance was assessed by examining the work done in raising reservoir pressure and that associated with the wave components of systolic PA pressure. Wave-related work, the mostly nonrecoverable energy expended by the RV to eject blood, tended to vary directly with mean PA pressure. Where PA pressures were lower, there were pressure-decreasing/flow-increasing backward waves that aided RV ejection. Where PA pressures were higher, there were pressure-increasing/flow-decreasing backward waves that impeded RV ejection. Pressure-increasing/flow-decreasing backward waves were responsible for systolic notches in the Doppler flow velocity profiles in patients with the highest PA pressure. Pulmonary hypertension is characterized by reflected waves that impede RV ejection and an increase in wave-related work. The RWA may facilitate the development of therapeutic strategies.
Beating Heart Validation of Safety and Efficacy of a Percutaneous Pericardiotomy Tool
Killu, Ammar M. , Naksuk, Niyada , Gaba, Prakriti , Suddendorf, Scott H., Powers, Joanne, Ladewig, Dorothy J., Lerman, Lilach O. , Borlaug, Barry A. , Asirvatham, Samuel J. , DeSimone, Christopher V. , Asirvatham, Samuel J , Borlaug, Barry A

Mayo Clinic

Journal of Cardiovascular Electrophysiology | October 19, 2016 | Volume: 28 | Issue: 3 | Pages: 357-361

10.1111/jce.13108 | PMID 27759180 Get It

Percutaneous Pericardiotomy ToolIntroductionEpicardial procedures frequently require pericardial manipulation. We aimed to develop a nonsurgical percutaneous pericardial modification tool that may (1) facilitate epicardial‐based procedures by enabling adhesiolysis or (2) attenuate the myocardial constraining effect of the pericardium.MethodsThree novel devices were developed to enable pericardiotomy, all of which can be deployed in over‐the‐wire fashion following percutaneous epicardial access. The grasper permits us to seize the pericardial membrane providing leverage for incision. The scissors enables anterograde cutting maneuvers. The reverse‐slitter allows retrograde incisions; in addition, this device has a deflectable tip that increases the potential cutting area. We optimized these tools for safety by including electrodes to test for phrenic nerve stimulation as well as myocardial stimulation to determine directionality of the cutting devices. The base of the scissors and reverse‐slitter are also blunt ensuring that the cutting element is always away from the myocardium.ResultsFollowing 5 nonbeating heart bench test experiments for prototype development, 11 animal (9 canine, 2 swine) studies were performed. Of these 2 were proof‐of‐concept open chest studies; the remaining 9 were entirely closed‐chest, percutaneous procedures allowing for remodification of the prototypes. The tools successfully permitted incision of the pericardium in all studies. Hemodynamic measurements were assessed postincision and showed no compromise of systolic function. No coronary artery or phrenic nerve damage was seen in any study.ConclusionPercutaneous pericardiotomy is feasible and appears to be safe. It may provide leverage in epicardial‐based procedures and offer treatment options in disease processes characterized by pericardial restraint.
Right Ventricular Dysfunction and Pulmonary Hypertension in Heart Failure with Preserved Ejection Fraction
Obokata, Masaru , Borlaug, Barry A. , Borlaug, Barry A , Obokata, Masaru

Mayo Clinic

European Journal of Heart Failure | October 13, 2016 | Volume: 18 | Issue: 12 | Pages: 1488-1490

10.1002/ejhf.666 | PMID 27734560 Get It

Myocardial Iron Content and Mitochondrial Function in Human Heart Failure: A Direct Tissue Analysis
Melenovský, Vojtěch , Petrák, Jir̆ı́ , Mráček, Tomáš , Beneš, Jan , Borlaug, Barry A. , Nůsková, Hana , Pluháček, Tomáš , Spaténka, J , Kovalčíková, Jana, Drahota, Z , Kautzner, Josef , Pirk, Jan, Houštěk, J , Mikešová, Jana , Borlaug, Barry A , Melenovský, Vojtěch

Mayo Clinic

European Journal of Heart Failure | September 20, 2016 | Volume: 19 | Issue: 4 | Pages: 522-530

10.1002/ejhf.640 | PMID 27647766 Get It

Abstract Aims Iron replacement improves clinical status in iron-deficient patients with heart failure (HF), but the pathophysiology is poorly understood. Iron is essential not only for erythropoiesis, but also for cellular bioenergetics. The impact of myocardial iron deficiency (MID) on mitochondrial function, measured directly in the failing human heart, is unknown. Methods and results Left ventricular samples were obtained from 91 consecutive HF patients undergoing transplantation and 38 HF-free organ donors (controls). Total myocardial iron content, mitochondrial respiration, citric acid cycle and respiratory chain enzyme activities, respiratory chain components (complex I–V), and protein content of reactive oxygen species (ROS)-protective enzymes were measured in tissue homogenates to quantify mitochondrial function. Myocardial iron content was lower in HF compared with controls (156 ± 41 vs. 200 ± 38 µg·g−1 dry weight, P < 0.001), independently of anaemia. MID (the lowest iron tercile in HF) was associated with more extensive coronary disease and less beta-blocker usage compared with non-MID HF patients. Compared with controls, HF patients displayed reduced myocardial oxygen2 respiration and reduced activity of all examined mitochondrial enzymes (all P < 0.001). MID in HF was associated with preserved activity of respiratory chain enzymes but reduced activity of aconitase and citrate synthase (by –26% and –15%, P < 0.05) and reduced expression of catalase, glutathione peroxidase, and superoxide dismutase 2. Conclusion Myocardial iron content is decreased and mitochondrial functions are impaired in advanced HF. MID in HF is associated with diminished citric acid cycle enzyme activities and decreased ROS-protecting enzymes. MID may contribute to altered myocardial substrate use and to worsening of mitochondrial dysfunction that exists in HF.
Late acute graft-versus-host disease: a prospective analysis of clinical outcomes and circulating angiogenic factors
Holtan, Shernan G. , Khera, Nandita , Levine, John E. , Chai, Xiaoyu , Storer, Barry E. , Liu, Hien , Inamoto, Yoshihiro , Mayer, Sebastian , Arora, Mukta , Palmer, Jeanne , Lukez, Alexander , Arai, Sally , Lazaryan, Aleksandr , Newell, Laura F. , Krupski, Christa , Jagasia, Madan , Pusic, Iskra , Wood, William A. , Renteria, Anne S. , Yanik, Gregory A. , Ayuk, Francis , Holler, Ernst , Watanaboonyongcharoen, Phandee , Efebera, Yvonne A. , Ferrara, James L.M. , Weisdorf, Daniel J. , Lee, Stephanie J. , Pidala, Joseph, Chen, George L. , Flowers, Mary E.D. , Cutler, Corey S. , Hogan, William J. , Hexner, Elizabeth O. , Panoskaltsis‐Mortari, Angela , Weisdorf, Dan , Levine, John E , Holtan, Shernan , Lee, Stephanie J , Wood, William A

Mayo Clinic

Blood | September 14, 2016 | Volume: 128 | Issue: 19 | Pages: 2350-2358

10.1182/blood-2015-09-669846 | PMID 27625357 Get It

Key Points Under current treatment approaches, patients with LA GVHD have poor overall and failure-free survival. Levels of AREG are elevated in LA GVHD, and the AREG/EGF ratio is predictive of overall survival and nonrelapse mortality in LA GVHD.
Effect of the look‐up line on the gaze and head orientation of elite ice hockey players
Vickers, Joan N., Causer, Joe , Stuart, Michael, Little, Elaine C, Dukelow, Sean P. , Lavangie, Marc, Nigg, Sandro, Arsenault, Gina, Morton, Barry, Scott, Matt , Emery, Carolyn A. , Emery, Carolyn A

Mayo Clinic

European Journal of Sport Science | August 31, 2016 | Volume: 17 | Issue: 1 | Pages: 109-117

10.1080/17461391.2016.1220627 | PMID 27577327 Get It

AbstractA “look‐up line” (LUL) has been proposed for ice hockey, which is an orange 1 m (40′) warning line (WL) painted on the ice at the base of the boards. The LUL purports to provide an early warning to players to keep their head up prior to and as they are being checked. We determined if players looked up more on a rink with the LUL compared to a traditional Control rink. Elite offensive (O) and defensive (D) players competed 1 vs. 1, while wearing an eye tracker that recorded their quiet eye (QE) and fixation and tracking (F‐T) and an electrogoniometer that measured head angle. External cameras recorded skate duration during four skate phases: P1 preparation, P2 decision‐making, P3 cut to boards, P4 contact. The QE was the final fixation prior to contact between O and D as they skated towards and across the WL during P3 and P4. Skate phase durations (%) did not differ by rink or rink by position. More QE and F‐T occurred on the WL on the LUL rink than on the Control. The expected increase in head angle on the LUL rink did not occur during P3 or P4. Post‐hoc results also showed O and D skated further from the boards on the LUL rink, suggesting the players preferred to control the puck on white ice, rather than the orange colour of the LUL rink. More research is needed to determine if these results apply to the competitive setting.
Lung Function Trajectory in Bronchiolitis Obliterans Syndrome after Allogeneic Hematopoietic Cell Transplant
Cheng, Guang‐Shing , Storer, Barry E. , Chien, Jason W. , Jagasia, Madan , Hubbard, Jesse J., Burns, Linda J. , Ho, Vincent T. , Pidala, Joseph, Palmer, Jeanne , Johnston, Laura , Mayer, Sebastian , Crothers, Kristina , Pusic, Iskra , Lee, Stephanie J. , Williams, Kirsten M. , Crothers, Kristina , Lee, Stephanie J

Mayo Clinic

Annals of the American Thoracic Society | August 11, 2016 | Volume: 13 | Issue: 11 | Pages: 1932-1939

10.1513/annalsats.201604-262oc | PMID 27513368 Get It

Abstract Rationale The natural history of lung function in patients with bronchiolitis obliterans syndrome (BOS) after allogeneic hematopoietic cell transplant is poorly characterized. Understanding the trajectory of lung function is necessary for prompt clinical recognition and treatment and also for the rational design of prospective studies. Objectives To describe the longitudinal trajectory of lung function parameters, including FEV1, in patients with BOS after hematopoietic cell transplant. Methods Subjects with BOS defined by National Institutes of Health consensus guidelines criteria from a recent multicenter prospective trial of combination treatment with fluticasone, azithromycin and montelukast and a retrospective cohort from Fred Hutchinson Cancer Research Center were included. Longitudinal change in FEV1 for each patient was calculated on the basis of available pulmonary function tests in three periods: pre-BOS, from BOS diagnosis to 6 months, and 6–18 months after diagnosis. The effect of treatment on FEV1 trajectory was analyzed by univariate and multivariate linear regression. The Kaplan-Meier method was used to estimate survival. Measurements and Main Results: The FEV1 percent predicted value at diagnosis was 46% (interquartile range, 35–57%) for trial participants and 53% (interquartile range, 41–64%) for the retrospective cohort. There was a concomitant mild reduction in FVC, as well as a marked reduction in forced expiratory flow, midexpiratory phase, at diagnosis. While there was individual heterogeneity, the overall FEV1 trajectory was characterized by a marked decline within 6 months prior to BOS diagnosis, followed by stability of FEV1 early after diagnosis and a slow rate of decline beyond 6 months. The effect of the trial medications on FEV1 trajectory after BOS diagnosis was a mean rate of change of 0.92% predicted per month (95% confidence interval, −0.53 to 2.37) compared with the retrospective cohort, but this was not statistically significant. Two-year overall survival rates were 76% and 72% for the study participants and the retrospective cohort patients, respectively. Earlier time to diagnosis after hematopoietic cell transplant and severity of FVC at diagnosis were significantly associated with reduced survival. Conclusions The FEV1 trajectory in patients with BOS after hematopoietic cell transplant in a contemporary era of management follows a predominant pattern of rapid FEV1 decline in the 6 months prior to diagnosis, followed by FEV1 stabilization after diagnosis.
Differential Response to Low-Dose Dopamine or Low-Dose Nesiritide in Acute Heart Failure With Reduced or Preserved Ejection Fraction
Wan, Siu‐Hin , Stevens, Susanna R., Borlaug, Barry A. , Anstrom, Kevin J. , Felker, G. Michael , Givertz, Michael M., Bart, Bradley A. , Tang, W.H. Wilson , Redfield, Margaret M. , Chen, Horng H. , Deswal, Anita M , Givertz, Michael M. , Borlaug, Barry A , Tang, W H Wilson

Mayo Clinic

Circulation: Heart Failure | August 11, 2016 | Volume: 9 | Issue: 8 | Pages: No page available

10.1161/circheartfailure.115.002593 | PMID 27512103 Get It

Background— The ROSE AHF trial (Renal Optimization Strategies Evaluation in Acute Heart Failure) found that when compared with placebo, neither low-dose dopamine (2 µg/kg per minute) nor low-dose nesiritide (0.005 μg/kg per minute without bolus) enhanced decongestion or preserved renal function in AHF patients with renal dysfunction. However, there may be differential responses to vasoactive agents in AHF patients with reduced versus preserved ejection fraction (EF). This post hoc analysis examined potential interaction between treatment effect and EF (EF ≤40% versus >40%) on the ROSE AHF end points. Methods and Results— ROSE AHF enrolled AHF patients (n=360; any EF) with renal dysfunction. The coprimary end points were cumulative urine volume and the change in serum cystatin-C in 72 hours. The effect of dopamine (interaction P =0.001) and nesiritide (interaction P =0.039) on urine volume varied by EF group. In heart failure with reduced EF, urine volume was higher with active treatment versus placebo, whereas in heart failure with preserved EF, urine volume was lower with active treatment. The effect of dopamine and nesiritide on weight change, sodium excretion, and incidence of AHF treatment failure also varied by EF group (interaction P <0.05 for all). There was no interaction between vasoactive treatment’s effect and EF on change in cystatin-C. Compared with placebo, dopamine was associated with improved clinical outcomes in heart failure with reduced EF and worse clinical outcomes in heart failure with preserved EF. With nesiritide, there were no differences in clinical outcomes when compared with placebo in both heart failure with reduced EF and heart failure with preserved EF. Conclusions— In this post hoc analysis of ROSE AHF, the response to vasoactive therapies differed in patients with heart failure with reduced EF and heart failure with preserved EF. Investigations of AHF therapies should assess the potential for differential responses in AHF with preserved versus reduced EF. Clinical Trial Registration— URL: http://www.clinicaltrials.gov . Unique identifier: NCT01132846.
A recurring mutation in the respiratory complex 1 protein NDUFB11 is responsible for a novel form of X-linked sideroblastic anemia
Lichtenstein, Daniel A. , Crispin, Andrew, Sendamarai, Anoop K. , Campagna, Dean R. , Schmitz‐Abe, Klaus , Sousa, Cristovão M. , Kafina, Martin D. , Schmidt, Paul J. , May, Alison, Patnaik, Mrinal M. , Kimmelman, Alec C. , Bottomley, Sylvia S. , Markianos, Kyriacos , Fleming, Mark D. , Niemeyer, Charlotte Marie , Porter, John B. , Heeney, Matthew M. , Paw, Barry H. , Lichtenstein, Dan

Mayo Clinic

Blood | August 4, 2016 | Volume: 128 | Issue: 15 | Pages: 1913-1917

10.1182/blood-2016-05-719062 | PMID 27488349 Get It

Key Points A recurring mutation in NDUFB11 causes congenital sideroblastic anemia. The NDUFB11 p.93del mutation impairs erythroid proliferation, but not differentiation.
Inhaled Sodium Nitrite Improves Rest and Exercise Hemodynamics in Heart Failure With Preserved Ejection Fraction
Borlaug, Barry A. , Melenovský, Vojtěch , Koepp, Katlyn E. , Borlaug, Barry A , Melenovský, Vojtěch

Mayo Clinic

Circulation Research | July 26, 2016 | Volume: 119 | Issue: 7 | Pages: 880-886

10.1161/circresaha.116.309184 | PMID 27458234 Get It

Rationale: Abnormalities in nitric oxide signaling play a pivotal role in heart failure with preserved ejection fraction (HFpEF). Intravenous sodium nitrite, which is converted to nitric oxide in vivo, improves hemodynamics in HFpEF, but its use is limited by the need for parenteral administration. Nitrite can also be administered using a novel, portable micronebulizer system suitable for chronic use. Objective: Determine whether inhaled nitrite improves hemodynamics in HFpEF. Methods and Results: In a double-blind, randomized, placebo-controlled, parallel-group trial, subjects with HFpEF (n=26) underwent cardiac catheterization with simultaneous expired gas analysis at rest and during exercise before and after treatment with inhaled sodium nitrite (90 mg) or placebo. The primary end point was the pulmonary capillary wedge pressure during exercise. Before study drug administration, HFpEF subjects displayed an increase in pulmonary capillary wedge pressure with exercise from 20±6 to 34±7 mm Hg ( P <0.0001). After study drug administration, exercise pulmonary capillary wedge pressure was substantially improved by nitrite as compared with placebo (baseline-adjusted mean 25±5 versus 31±6 mm Hg; analysis of covariance P =0.022). Inhaled nitrite reduced resting pulmonary capillary wedge pressure (−4±3 versus −1±2 mm Hg; P =0.002), improved pulmonary artery compliance (+1.5±1.1 versus +0.6±0.9 mL/mm Hg), and decreased mean pulmonary artery pressures at rest (−7±4 versus −3±4 mm Hg; P =0.007) and with exercise (−10±6 versus −5±6 mm Hg; P =0.05). Nitrite reduced right atrial pressures, with no effect on cardiac output or stroke volume. Conclusions: Acute administration of inhaled sodium nitrite reduces biventricular filling pressures and pulmonary artery pressures at rest and during exercise in HFpEF. Further study is warranted to evaluate chronic effects of inhaled nitrite in HFpEF. Clinical Trial Registration: This single center randomized clinical trial is registered at clinicaltrials.gov (NCT02262078).